

WOCKHARDT'S TRANSFORMATION

Amongst the Top 3 Pharma Companies

with

101% Growth in Profit After Tax at Rs.428 crores

51% Growth in Operating Profit at Rs. 545 crores

26% Growth in Revenues at Rs. 1435 crores

in 3rd Quarter of 2012-13



	Q3-FY13		Q3-FY12	9M-FY13		9M-FY12	FY12
	Oct - Dec 2012		Oct - Dec 2011	Apr - Dec 2012		Apr - Dec 2011	
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y	Rsc	
Sales	1,435	26%	1,141	4,124	30%	3,174	4,351
Operating Profit	545	51%	361	1,545	61%	961	1,377
Op. Profit Margins %	38.0%		31.6%	37.5%		30.3%	32%
Profit After Tax	428	101%	213	1,259	136%	534	343
PAT Margins	29.8%		18.7%	30.5%		16.8%	8%
EPS (Adj. PAT)	39.1	101%	19.4	115.0	136%	48.8	31.3

Q3FY13

Wockhardt Limited, the Pharmaceutical and Biotechnology major, continues to be amongst the Top 3 profitable company in the Pharmaceutical industry in India. It has reported a Profit After Tax in Q3FY13 of Rs.428 crores which is more than 100% growth over the corresponding quarter of Financial Year 2011-12. The Profit After Tax margin is at 30%. This is amongst the best in India.

Wockhardt's Operating Profit for Q3FY13 stands at Rs. 545 crores, with Operating Profit Margin at 38.0% for the quarter, one of the highest in the industry and has improved from 31.6% in the corresponding quarter of the previous year.

The R&D expenses for the quarter were at 6.4% to sales and represented a growth of 80% over the corresponding quarter of Financial Year 2011-12.

Consolidated revenues grew by 26% to Rs.1,435 Crores over the corresponding quarter of Financial Year 2011-12.

Nine Months ended Dec. 31st 2012 (9MFY13)

The Profit After Tax for 9MFY13 2012-13 stood at Rs. 1259 crores and represented a growth of 136% over same period in the previous year.

PRESS RELEASE



The Operating Profit was at Rs.1545 crores for 9MFY13, representing a growth of 61% over same period in the previous year. Operating Profit margins were at 37.5% for 9MFY13.

Consolidated revenues grew by 30% to Rs. 4,124 crores over the corresponding half year of Financial Year 2011-12.

Other Financials

The Earnings Per Share was at Rs. 115 for the Nine months ended Dec. 31st 2012.

Business Highlights

Wockhardt's International Business contributed 83% of the Total Revenues during the quarter.

Wockhardt's US business recorded a growth of 45% compared to the corresponding quarter of Financial Year 2011-12. During the quarter the company received 3 product approvals. The growth in the US market was mainly driven by niche launches made during 2012, with generic version of brands like;

- Prevacid® (Lansoprazole)
- Geodon® (Ziprasidone)
- Flonase® (Fluticasone)
- Stalevo® (Levodopa, Entacapone, Carbidopa)
- Comtan® (Entacapone)

- Prevacid® is a registered trademark of Takeda Pharmaceutical USA Inc.
- Geodon® is a registered trademark of Pfizer Inc.
- Flonase® is a registered trademark of Glaxo Smithkline.
- Stalevo® is a registered trademark of Orion Corporation.
- Comtan® is a registered trademark of Orion Corporation.

The UK business recorded a growth of 19% compared to the corresponding quarter of Financial Year 2011-12 in an otherwise stagnant market. The Irish market recorded a growth of 3% compared to the corresponding quarter of Financial Year 2011-12.

The India business grew by 14% and the Emerging Markets business grew by 18% compared to the corresponding quarter of Financial Year 2011-12.

Wockhardt Limited has organized a conference call and webcast for investors and analysts on Thursday, February 15, 2013 from 11am - 12noon IST. The details of the webcast and conference call are as follows:

Timing	:	11:00 am IST on Friday, February 15, 2013
¹Webcast link	:	http://cs3-ipresent.choruscall.com/FlexPresenter
¹Webcast user-name	:	<your name>
¹Webcast passcode	:	6389108
²Conference dial-in Primary number	:	+91 22 6629 0301 / +91 22 3065 0122
Hong Kong Local Access Number	:	800 964 448
Singapore Local Access Number	:	800 101 2045
UK Local Access Number	:	0 808 101 1573
USA Local Access Number	:	1 866 746 2133
Replay Facility	:	Available until February 22, 2013 on + 91 22 3065 1212 Play Back ID – 12741# Replay will be available 2 hours after the call ends

¹For viewing the presentation while it is being discussed by the management

²For audio and the question and answer session

About Wockhardt :

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 80% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 193 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7900 people from 21 different nationalities.